Stifel Nicolaus Increases uniQure (NASDAQ:QURE) Price Target to $32.00

uniQure (NASDAQ:QURE) had its target price raised by stock analysts at Stifel Nicolaus from $12.00 to $32.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ target price suggests a potential upside of 107.79% from the stock’s current price.

A number of other equities analysts have also commented on the company. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Royal Bank of Canada lifted their price target on uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Leerink Partners boosted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. The Goldman Sachs Group raised their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.13.

uniQure Price Performance

NASDAQ:QURE opened at $15.40 on Monday. The company has a 50-day moving average of $7.04 and a 200-day moving average of $6.38. uniQure has a 52 week low of $3.73 and a 52 week high of $17.39. The company has a market capitalization of $750.60 million, a price-to-earnings ratio of -3.10 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, equities research analysts anticipate that uniQure will post -3.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC lifted its position in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Geode Capital Management LLC lifted its position in uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after acquiring an additional 6,362 shares during the last quarter. American Century Companies Inc. raised its position in shares of uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares during the last quarter. Finally, RTW Investments LP purchased a new position in uniQure in the 3rd quarter worth $49,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.